Holen Sie sich die Stockscreener-App
4.37
25.85%
-1.51
Handel nachbörslich:
4.50
0.13
+2.97%
Schlusskurs vom Vortag:
$5.88
Offen:
$5.95
24-Stunden-Volumen:
2.47M
Relative Volume:
12.62
Marktkapitalisierung:
$31.51M
Einnahmen:
$100.44M
Nettoeinkommen (Verlust:
$-133.16M
KGV:
-0.1696
EPS:
-25.76
Netto-Cashflow:
$-94.85M
1W Leistung:
-70.08%
1M Leistung:
-75.77%
6M Leistung:
-52.76%
1J Leistung:
-73.07%
1-Tages-Spanne:
$4.2518
$5.96
1-Wochen-Bereich:
$4.2518
$17.98
52-Wochen-Spanne:
$4.2518
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Vergleichen Sie ATRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
4.37 | 42.40M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.67 | 116.86B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
758.91 | 80.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
810.51 | 49.26B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
369.96 | 49.00B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.06 | 36.96B | 4.98B | 69.59M | 525.67M | 0.5197 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
Canaccord Genuity Downgrades Atara Biotherapeutics (ATRA) to Hol - GuruFocus
Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier) - TipRanks
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Atara receives FDA complete response letter for Ebvallo BLA application - Pharmaceutical Business review -
FDA rejects Atara’s tabelecleucel application in surprise reversal By Investing.com - Investing.com Nigeria
Atara Biotherapeutics Stock Falls After FDA CRL On EBVALLO BLA - RTTNews
FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain - TipRanks
FDA rejects Atara’s tabelecleucel application in surprise reversal - Investing.com
Atara Biotherapeutics (ATRA) Shares Plunge After FDA Setback - GuruFocus
Atara plummets on FDA Complete Response Letter for tabelecleucel - Seeking Alpha
ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’ - Asianet Newsable
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
FDA Hits Atara Biotherapeutics’ T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD With Second CRL - CGTLive®
Atara, Pierre Fabre allege FDA about-face as agency hands down 2nd Ebvallo snub - Fierce Pharma
Why Is Atara Biotherapeutics Stock Sinking Monday?Atara Biotherapeutics (NASDAQ:ATRA) - Benzinga
US FDA declines to approve Atara's therapy for rare blood cancer - Reuters
Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next - TechStock²
FDA Rejects Atara's (ATRA) Ebvallo BLA: Calls for New Evidence o - GuruFocus
US FDA declines to approve Atara’s therapy for rare blood cancer - PharmaLive
Atara's cell therapy is again rejected by FDA, cites agency reversing position on single-arm study - Endpoints News
FDA says unable to approve Atara Biotherapeutics Ebvallo BLA in present form - TipRanks
Atara Biotherapeutics stock plunges after FDA rejects cancer therapy By Investing.com - Investing.com UK
Atara Biotherapeutics stock plunges after FDA rejects cancer therapy - Investing.com
FDA says no to rare transplant cancer treatment patients awaited - Stock Titan
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel) - Business Wire
Why Atara Biotherapeutics Inc. stock could be next big winnerJuly 2025 Sentiment & Weekly High Conviction Ideas - Улправда
Why Atara Biotherapeutics Inc. stock is a value investor pickWeekly Trading Summary & Low Risk High Win Rate Picks - ulpravda.ru
Is Atara Biotherapeutics Inc. stock safe for conservative investorsProfit Target & Low Risk High Reward Ideas - Улправда
Why Atara Biotherapeutics Inc. stock attracts global investorsEarnings Trend Report & Risk Controlled Swing Alerts - ulpravda.ru
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip - MSN
Atara Biotherapeutics prices $16M public offering - MSN
Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears - TipRanks
How Atara Biotherapeutics Inc. stock performs in interest rate cyclesMarket Volume Summary & Fast Moving Stock Trade Plans - Улправда
Atara revises tab-cel commercialization milestones with Pierre Fabre - MSN
FDA Decisions to Look For in 1H 2026 - CGTLive®
สล็อตเว็บตรง www.offroadpakistan.com - Early Times
(ATRA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Atara Biotherapeutics IncEntered fourth amendment with Pierre FabreSEC filing - marketscreener.com
Weekly Analysts’ Ratings Changes for Atara Biotherapeutics (ATRA) - Defense World
How Atara Biotherapeutics Inc. stock performs in stagflationHead and Shoulders Patterns & Easy Tools to Analyze Your Investment Risk - bollywoodhelpline.com
Technical Reactions to ATRA Trends in Macro Strategies - Stock Traders Daily
Biotech Stocks Facing FDA Decision In January 2026 - RTTNews
Can Atara Biotherapeutics Inc. stock deliver consistent earnings growthShort Interest Overview & Superior Trading Portfolio - bollywoodhelpline.com
Atara Biotherapeutics (ATRA) Price Target Increased by 15.69% to 20.06 - Nasdaq
Aug Outlook: Is Atara Biotherapeutics Inc. stock a good choice for value investors2025 Volume Leaders & AI Powered Market Trend Analysis - Улправда
Hedge Fund Bets: Can Atara Biotherapeutics Inc. stock deliver consistent earnings growthInsider Buying & Accurate Buy Signal Alerts - Улправда
Atara Biotherapeutics Earnings Notes - Trefis
Atara Biotherapeutics (ATRA) Sees Price Target Increase by Canac - GuruFocus
Is Atara Biotherapeutics Inc. (AT20) stock worth holding before Fed meetingEarnings Beat & Reliable Breakout Forecasts - Улправда
Can Atara Biotherapeutics Inc. stock surprise with earnings upsideJuly 2025 Drop Watch & Low Risk High Reward Trade Ideas - DonanımHaber
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.20%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):